TrialBMC infectious diseases2017

The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study.

Kristin Brekke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.